Company Number: 12545004

Analysis Date: 2025-07-20 12:23 UTC

Financial Health Assessment for BIOIS UK LTD

---

1. Financial Health Score: D

Explanation:
BIOIS UK LTD shows concerning signs of financial distress with negative net assets and declining cash reserves. The company’s ability to meet short-term obligations is weak, and accumulated losses have eroded shareholder equity. While the business remains active and filing on time, its financial "vital signs" indicate it is currently in an unhealthy state requiring urgent attention.

---

2. Key Vital Signs

Metric	2024 Value (£)	Interpretation
Net Assets	-647	Negative net worth shows liabilities exceed assets; symptom of insolvency risk.
Cash at Bank	520	Low cash reserves indicate tight liquidity; cash flow is "weak pulse."
Current Liabilities	1,668	Short-term debts higher than cash and net current assets; risk of default.
Net Current Assets	-1,148	Negative working capital signals inability to cover short-term debts.
Shareholders Funds	-647	Equity is negative due to accumulated losses ("profit and loss reserve" at -747).
Fixed Assets (Tangible)	501	Small asset base, mostly computer equipment; limited collateral value.
Profit and Loss Account	-747	Accumulated losses have grown over time, indicating sustained losses.
Employee Count	2	Very small team reflecting micro/small scale operations.

---

3. Diagnosis: What the Numbers Reveal

BIOIS UK LTD presents multiple "symptoms of financial distress":

• Negative Net Assets & Equity: The company’s total liabilities exceed its assets by £647, a critical indicator of financial weakness. This equates to a state of "underlying illness" where the business has been losing money over time, eroding its capital base.

• Weak Liquidity: Cash reserves have dropped from £1,360 in 2023 to just £520 in 2024, while current liabilities remain high at £1,668. This means the company does not have enough "healthy blood flow" (cash) to easily cover its immediate obligations.

• Negative Working Capital: Net current assets are negative (-£1,148), suggesting that the company may face difficulty paying bills and suppliers on time, potentially leading to operational disruptions.

• Declining Fixed Assets: Slight reduction in tangible fixed assets (computer equipment) but this is not a major concern given the small asset base.

• Sustained Losses: The profit and loss reserve is negative and worsening, indicating that the company is not generating profits and is burning through capital.

• Small Scale Operation: With only two employees and minimal capital (£100 share capital), the company is a small startup-like entity with limited resources.

Overall, BIOIS UK LTD’s financial health is fragile, akin to a patient showing signs of chronic illness without immediate recovery signs. The company is technically solvent (not in liquidation or administration) but very close to financial distress.

---

4. Recommendations: Prescription for Financial Wellness

1. Improve Cash Flow Management:

   • Accelerate receivables collection and manage payables to improve liquidity.
   • Explore short-term financing options (overdraft, invoice financing) to stabilize cash flow.

2. Cost Control and Expense Reduction:

   • Review operational expenses to reduce cash outflows.
   • Consider lean operational models or temporary cost-saving measures.

3. Capital Injection:

   • Seek additional equity investment or shareholder loans to rebuild capital and restore positive net assets.
   • Alternatively, explore grants or funding specific to biotech research startups.

4. Strategic Business Review:

   • Evaluate revenue generation capability and business model to reverse losses.
   • Focus on core competencies in biotechnology R&D; consider partnerships or collaborations.

5. Regular Financial Monitoring:

   • Implement monthly cash flow forecasts and key financial metrics tracking.
   • Early detection of financial stress symptoms can allow timely interventions.

6. Engage Professional Advice:

   • Consider financial restructuring advice or turnaround specialists familiar with biotech startups.

In medical terms, BIOIS UK LTD needs urgent intervention to stabilize its financial "vital signs," improve liquidity "heartbeat," and halt the decline in "capital health" to avoid a potential financial "collapse."

---